Takeda Pharmaceuticals North America Inc. has launched an ad campaign for its new sleeping pill, Rozerem. Rozerem was approved by the Food and Drug Administration last year as the first sleeping medication not designated as a controlled substance, therefore lacking potential for abuse.
The company and studies indicate the drug lacks the risk of chemical abuse or dependency that other prescription sleeping aids pose. Rozerem will compete against drugs like Ambien and Lunesta, both of which list the potential for dependency in their labels.
Leave a comment